This poster was presented at the British Thoracic Oncology Group conference, 2025. It aims to elicit expert clinical judgements on important factors for treatment decisions in advanced ALK-positive NSCLC, clinical monitoring requirements for treatment, perceived toxicity of ALK-TKIs, best practices in shared decision-making and key clinical priorities.
What is the consistency of response to rimegepant at a group level in the acute treatment of migraine in UK adult patients? Protocol for a real-world, patient-centred study
O’Neil G, Abraham L, Pawinski R, Nakajima K, Bagshaw E, Fellows A, Llewellyn S, Lambru G (EHC, 2025)


Copy Link